Work

Mitochondrial Membrane Permeability Inhibitors in Acute Myocardial Infarction

Year: 2016

Type: article

Abstract: Despite therapeutic advances, acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality worldwide. One potential limitation of the current treatment paradigm is the lack of effective therapies to optimize reperfusion after ischemia and prevent reperfusion-mediated injury. Experimental studies indicate that this process accounts for up to 50% of the final infarct size, lending it importance as a potential target for cardioprotection. However, multiple therapeutic approaches have shown potential in pre-clinical and early phase trials but a paucity of clear clinical benefit when expanded to larger studies. Here we explore this history of trials and errors of the studies of cyclosporine A and other mitochondrial membrane permeability inhibitors, agents that appeared to have a promising pre-clinical record yet provided disappointing results in phase III clinical trials.

Source: JACC Basic to Translational Science

DOI: 10.1016/j.jacbts.2016.06.012

Authors: Cory Trankle, Clinton J. Thurber, Stefano Toldo, Antonio Abbate

Institutions: Virginia Commonwealth University, Virginia Commonwealth University Medical Center, Sapienza University of Rome

Language: English

Topic: Cardiac Ischemia and Reperfusion

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,750